-
公开(公告)号：US08309600B2
公开(公告)日：2012-11-13
申请号：US12641263
申请日：2009-12-17
Applicant: Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
Inventor： Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
IPC: A61K31/343 , C07D307/83
CPC classification number: C07D405/04 , C07D213/64 , C07D231/56 , C07D235/12 , C07D307/79 , C07D307/80 , C07D307/83 , C07D307/94 , C07D311/58 , C07D319/08 , C07D333/54 , C07D333/60 , C07D405/10 , C07D407/04 , C07D407/12
Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
-
公开(公告)号：US08299117B2
公开(公告)日：2012-10-30
申请号：US12817116
申请日：2010-06-16
Applicant: Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
Inventor： Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
IPC: A61K31/343 , C07D307/83
CPC classification number: C07D209/08 , A61K31/343 , A61K31/352 , A61K31/357 , A61K31/381 , A61K31/41 , A61K31/416 , A61K31/44 , C07B59/002 , C07D211/76 , C07D231/56 , C07D307/79 , C07D307/83 , C07D307/94 , C07D311/58 , C07D319/08 , C07D333/54 , C07D405/10
Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Abstract translation: 提供GPR120激动剂。 这些化合物可用于治疗代谢疾病，包括II型糖尿病和与血糖控制不良相关的疾病。
-
公开(公告)号：US08153818B2
公开(公告)日：2012-04-10
申请号：US12753342
申请日：2010-04-02
Applicant: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
Inventor： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC: C07D249/00
CPC classification number: C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
Abstract translation: 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
公开(公告)号：US20100216827A1
公开(公告)日：2010-08-26
申请号：US12582610
申请日：2009-10-20
Applicant: Jingyuan Ma , Aaron Novack , Imad Nashashibi , Phuongly Pham , Christopher J. Rabbat , Jiangao Song , Dong Fang Shi , Zuchun Zhao , Yun-Jung Choi , Xin Chen
Inventor： Jingyuan Ma , Aaron Novack , Imad Nashashibi , Phuongly Pham , Christopher J. Rabbat , Jiangao Song , Dong Fang Shi , Zuchun Zhao , Yun-Jung Choi , Xin Chen
IPC: A61K31/506 , C07D231/12 , A61K31/415 , C07D285/06 , A61K31/433 , C07D233/54 , A61K31/4164 , C07D403/04 , A61P3/10
CPC classification number: C07D231/12 , C07D233/64 , C07D249/06 , C07D261/08 , C07D263/32 , C07D277/24 , C07D285/06 , C07D307/42 , C07D333/16 , C07D409/04
Abstract: Aryl GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Abstract translation: 提供Aryl GPR120激动剂。 这些化合物可用于治疗代谢疾病，包括II型糖尿病和与血糖控制不良相关的疾病。
-
5.发明授权N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides 有权N-（2-（杂芳基）芳基）芳基磺酰胺和N-（2-（芳基）芳基芳基磺酰胺公开(公告)号：US08198309B2
公开(公告)日：2012-06-12
申请号：US12832374
申请日：2010-07-08
Applicant: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
Inventor： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
IPC: A01N43/64 , A01N43/50 , A01N43/56 , A61K31/41 , A61K31/415 , C07D403/00 , C07D231/00 , C07D233/61 , C07D231/10 , C07D231/12 , C07D277/28
CPC classification number: C07D473/00 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4192 , A61K31/437 , A61K31/496 , A61K31/52 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/08 , C07D249/06 , C07D249/18 , C07D401/04 , C07D401/14 , C07D403/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C12N2501/999
Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
Abstract translation: 提供了作为CCR9受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR9的特征性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR9介导的疾病的方法，以及用于鉴定CCR9拮抗剂的测定中的对照。
-
Patent Agency Ranking
公开(公告)号：US20100190831A1
公开(公告)日：2010-07-29
申请号：US12641263
申请日：2009-12-17
Applicant: Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
Inventor： Dong Fang Shi , Jiangao Song , Jingyuan Ma , Aaron Novack , Phuongly Pham , Imad Fayek Nashashibi , Christopher J. Rabbat , Xin Chen
IPC: A61K31/44 , C07D307/79 , A61K31/343 , A61P3/10 , C07D311/58 , A61K31/352 , C07D319/08 , A61K31/357 , C07D307/83 , C07D405/10 , A61K31/41 , C07D333/60 , A61K31/381 , C07D307/94 , C07D213/643
CPC classification number: C07D405/04 , C07D213/64 , C07D231/56 , C07D235/12 , C07D307/79 , C07D307/80 , C07D307/83 , C07D307/94 , C07D311/58 , C07D319/08 , C07D333/54 , C07D333/60 , C07D405/10 , C07D407/04 , C07D407/12
Abstract: GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.
Abstract translation: 提供GPR120激动剂。 这些化合物可用于治疗代谢疾病，包括II型糖尿病和与血糖控制不良相关的疾病。
-
公开(公告)号：US07557213B2
公开(公告)日：2009-07-07
申请号：US11599183
申请日：2006-11-13
Applicant: Anita Melikian , John Jessen Wright , Antoni Krasinski , Cheng Hu , Aaron Novack
Inventor： Anita Melikian , John Jessen Wright , Antoni Krasinski , Cheng Hu , Aaron Novack
IPC: C07D215/233 , A61K31/4709
CPC classification number: C07D401/06 , C07D215/233 , C07D401/10 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D491/056 , C07D519/00
Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
Abstract translation: 提供取代的喹诺酮化合物和组合物以及用于治疗疾病和病症如癌症的那些化合物的方法。
-
公开(公告)号：US20070167443A1
公开(公告)日：2007-07-19
申请号：US11599183
申请日：2006-11-13
Applicant: Anita Melikian , John Wright , Antoni Krasinski , Cheng Hu , Aaron Novack
Inventor： Anita Melikian , John Wright , Antoni Krasinski , Cheng Hu , Aaron Novack
IPC: A61K31/541 , A61K31/5377 , A61K31/503 , A61K31/496 , A61K31/4709 , C07D487/02 , C07D417/02 , C07D413/02 , C07D403/02
CPC classification number: C07D401/06 , C07D215/233 , C07D401/10 , C07D401/14 , C07D405/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D491/04 , C07D491/056 , C07D519/00
Abstract: Substituted quinolone compounds and compositions are provided along with methods for the use of those compounds in the treatment of diseases and disorders such as cancer.
Abstract translation: 提供取代的喹诺酮化合物和组合物以及用于治疗疾病和病症如癌症的那些化合物的方法。
-
公开(公告)号：US08481579B2
公开(公告)日：2013-07-09
申请号：US13411171
申请日：2012-03-02
Applicant: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
Inventor： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M. K. Pennell , Sreenivas Punna , Edward J. Sullivan , Xuefei Tan , William D. Thomas , Solomon Ungashe , Yibin Zeng
IPC: A61K31/44 , A61K31/50 , C07D207/04 , C07D249/00
CPC classification number: C07D249/08 , C07D401/04 , C07D403/04 , C07D405/04 , C07D413/04
Abstract: Compounds are provided that act as potent antagonists of the CCR2 or CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2 and CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, CCR9-mediated diseases, as controls in assays for the identification of CCR2 antagonists and as controls in assays for the identification of CCR9 antagonists.
Abstract translation: 提供了作为CCR2或CCR9受体的有效拮抗剂的化合物。 动物试验表明，这些化合物可用于治疗炎症，CCR2和CCR9的标志性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR2介导的疾病，CCR9介导的疾病的方法，作为用于鉴定CCR2拮抗剂的测定中的对照和用于鉴定CCR9拮抗剂的测定中的对照 。
-
10.发明申请N-(2-(HETARYL)ARYL)ARYLSULFONAMIDES AND N-(2-(HETARYL)HETARYL ARYLSULFONAMIDES 有权N-（2-（HETARYL）ARYL）ARYLSULFONAMIDES和N-（2-（HETARYL））乙酰氨基磺酰胺公开(公告)号：US20120245138A1
公开(公告)日：2012-09-27
申请号：US13462393
申请日：2012-05-02
Applicant: Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M.K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
Inventor： Trevor T. Charvat , Cheng Hu , Anita Melikian , Aaron Novack , Andrew M.K. Pennell , Edward J. Sullivan , William D. Thomas , Solomon Ungashe , Penglie Zhang , Jay Powers , Sreenivas Punna
IPC: C07D471/04 , C12N5/07 , C07D249/06 , A61K31/4192 , C07D231/14 , A61K31/415 , C07D233/61 , A61K31/4164 , C07D209/04 , A61K31/404 , C07D231/56 , C07D249/18 , C07D473/00 , A61K31/52 , C07D403/06 , A61K31/496 , C07D295/12 , A61K31/5377 , C07D401/14 , A61K31/444 , A61P1/00 , A61P37/08 , A61P17/06 , A61P17/00 , A61P37/06 , A61P19/02 , A61P35/02 , A61P35/00 , A61K31/437
CPC classification number: C07D473/00 , A61K31/404 , A61K31/415 , A61K31/4164 , A61K31/4192 , A61K31/437 , A61K31/496 , A61K31/52 , A61K31/5377 , A61K45/06 , C07D209/08 , C07D231/12 , C07D231/14 , C07D231/16 , C07D231/56 , C07D233/61 , C07D235/06 , C07D235/08 , C07D249/06 , C07D249/18 , C07D401/04 , C07D401/14 , C07D403/06 , C07D413/04 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C12N2501/999
Abstract: Compounds are provided that act as potent antagonists of the CCR9 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR9. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR9-mediated diseases, and as controls in assays for the identification of CCR9 antagonists.
Abstract translation: 提供了作为CCR9受体的有效拮抗剂的化合物。 动物实验表明，这些化合物可用于治疗炎症，CCR9的特征性疾病。 化合物通常为芳基磺酰胺衍生物，并且可用于药物组合物，用于治疗CCR9介导的疾病的方法，以及用于鉴定CCR9拮抗剂的测定中的对照。
-
-
-
-
-
-
-
-
-
Search Results
23
records
(took 0.043 seconds)
